Drug Profile
Research programme: long-acting muscarinic antagonists - Innoviva
Alternative Names: LAMA programme - InnovivaLatest Information Update: 23 Nov 2016
Price :
$50
*
At a glance
- Originator Theravance
- Class Small molecules
- Mechanism of Action Muscarinic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Chronic obstructive pulmonary disease
Most Recent Events
- 18 Dec 2007 A lead compound from this programme has entered clinical trials
- 12 Feb 2007 GSK and Theravance are still preclinically developing long-acting muscarinic antagonists
- 31 Aug 2004 Theravance's LAMA programme has been licensed to GlaxoSmithKline worldwide